ImmunoMet Therapeutics is a clinical-stage biotechnology company focused on developing innovative oncology and fibrosis treatments. The company's approach centers on targeting cellular metabolism to create novel therapies for cancer patients and those with fibrotic conditions. ImmunoMet's research and development efforts aim to harness metabolic reprogramming across multiple therapeutic areas, with a particular emphasis on improving the quality of life for cancer patients.
The company's lead candidate, IM156, has entered clinical trials, with a Phase 1b study in pancreatic cancer patients recently initiated. This milestone underscores ImmunoMet's progress in translating its metabolic-based approach from laboratory research to potential clinical applications. The company's pipeline and development programs reflect its commitment to addressing unmet medical needs in oncology and fibrosis through innovative metabolic-targeted therapies.
